Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

332 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-31

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

NCT02869802

Cancer Pancreatic Cancer

RECRUITING

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

NCT06574620

Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Ductal Adenocarcinoma Borderline Resectable Pancreatic Ductal Adenocarcinoma +1 more

RECRUITING NA

Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial

NCT05927298

Pancreas Cancer

RECRUITING

Pancreatic Adenocarcinoma Gene Environment Risk Study

NCT00912717

Pancreatic Cancer

RECRUITING

NGS and TME for Evidence-based Treatment of Pancreatic Cancer

NCT02767700

Pancreatic Ductal Adenocarcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Pancreatic Ductal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with advanced pancreatic ductal adenocarcinoma

Molecular Profiling

Intervention Type GENETIC

Whole Genome Sequencing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Molecular Profiling

Whole Genome Sequencing

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have a histological or radiological diagnosis of locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients with borderline resectable disease are not eligible.
* Patient must have a tumor lesion that is amenable to a core needle biopsy.
* Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied.
* Patients must be fit enough to safely undergo a tumor biopsy.
* Age 18 years or older.
* Eastern Cooperative Group (ECOG) performance status of 1 or less.
* Life expectancy of greater than 90 days.
* Patients must have normal organ and marrow function
* Patients must undergo systemic treatment with m-FOLFIRINOX or nab-paclitaxel as a first line standard systemic palliative treatment or combination treatment with m-FOLFIRINOX or nab-paclitaxel with or without other investigational agents within a clinical trial as a first line palliative treatment.
* Ability to understand and willing to sign a written informed consent document.

Exclusion Criteria

* Patients with one or more contraindications to tumor biopsy.
* Patients who have prior systemic treatment (chemotherapy or any other anti-cancer agent) in advanced setting.
* Patients who are currently on anti-cancer treatment including chemotherapy.
* Patients with known brain metastases.
* Patients with advanced PDAC who are going to be treated with gemcitabine monotherapy in advanced setting.
* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No